Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Zelboraf® (vemurafenib) – New warning
September 22, 2017 – The FDA approved an update to the Warnings and Precautions section of the Zelboraf (vemurafenib) drug label regarding Dupuytren’s contracture and plantar fascial fibromatosis.
